Mats Heyman Selected Research

Mats Heyman Research Topics

Disease

32	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2022 - 08/2005
10	Neoplasms (Cancer) 01/2021 - 08/2008
6	Leukemia 12/2022 - 02/2008
5	Hypersensitivity (Allergy) 01/2021 - 03/2015
5	Pancreatitis 01/2021 - 04/2014
4	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2019 - 06/2007
4	Infections 01/2019 - 02/2008
3	Thrombosis (Thrombus) 01/2022 - 02/2015
3	Residual Neoplasm 01/2019 - 05/2013
2	Seizures (Absence Seizure) 01/2022 - 07/2020
2	Anaphylaxis (Anaphylactic Shock) 01/2022 - 03/2015
2	Hemorrhage 01/2022 - 02/2015
2	Down Syndrome (Down's Syndrome) 01/2021 - 04/2011
2	Disease Progression 01/2019 - 04/2014
2	Hematologic Neoplasms (Hematological Malignancy) 02/2017 - 02/2008
1	Renal Insufficiency (Renal Failure) 01/2022
1	Posterior Leukoencephalopathy Syndrome 01/2022
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2019
1	Osteonecrosis (Kienbock's Disease) 01/2019
1	Pancreatic Pseudocyst 01/2019
1	Thromboembolism 01/2019
1	Virus Diseases (Viral Diseases) 01/2018
1	Bacterial Infections (Bacterial Infection) 01/2018
1	Second Primary Neoplasms (Neoplasms, Second) 10/2017
1	Hypertriglyceridemia 10/2017
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2017
1	Philadelphia Chromosome 02/2016
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2013
1	Multiple Myeloma 01/2013
1	T-Cell Leukemia (Leukemia, T Cell) 04/2012
1	Chromosome Aberrations (Chromosome Abnormalities) 03/2011
1	Erythema Infectiosum (Fifth Disease) 02/2008
1	Cytopenia 02/2008
1	Viremia 02/2008

Drug/Important Bio-Agent (IBA)

10	Asparaginase (Elspar)FDA Link 11/2022 - 04/2014
8	Mercaptopurine (6 Mercaptopurine)FDA LinkGeneric 05/2022 - 06/2009
7	Methotrexate (Mexate)FDA LinkGeneric 05/2022 - 06/2009
4	Pharmaceutical PreparationsIBA 01/2019 - 08/2008
3	EnzymesIBA 11/2022 - 01/2019
3	pegaspargase (Oncaspar)FDA Link 01/2021 - 03/2015
2	UbiquitinIBA 12/2022 - 06/2007
2	2-mercaptopurineIBA 05/2022 - 10/2017
2	Dexamethasone (Maxidex)FDA LinkGeneric 07/2020 - 11/2007
2	DeoxycytidineIBA 01/2020 - 02/2017
2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2020 - 02/2017
2	RNA (Ribonucleic Acid)IBA 01/2019 - 12/2013
2	thiopurine methyltransferase (thiopurine S-methyltransferase)IBA 10/2017 - 05/2014
2	GlucocorticoidsIBA 10/2012 - 11/2007
2	Dacarbazine (DIC)FDA LinkGeneric 03/2011 - 02/2008
1	Thioguanine (Tioguanine)FDA Link 05/2022
1	insulin receptor-related receptor (IRR)IBA 01/2022
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 01/2019
1	AntigensIBA 01/2019
1	AsparagineIBA 01/2019
1	CoagulaseIBA 01/2019
1	Insulin (Novolin)FDA Link 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	AntithrombinsIBA 10/2017
1	LipidsIBA 10/2017
1	Proteins (Proteins, Gene)FDA Link 02/2017
1	Cytostatic AgentsIBA 02/2017
1	KIR ReceptorsIBA 01/2017
1	SteroidsIBA 02/2015
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 02/2015
1	Biological ProductsIBA 01/2015
1	antiarrhythmic peptide (AAP)IBA 04/2014
1	Messenger RNA (mRNA)IBA 03/2014
1	Bortezomib (Velcade)FDA Link 01/2013
1	ATP dependent 26S protease (26S proteasome)IBA 01/2013
1	MicroRNAs (MicroRNA)IBA 10/2012
1	Angiogenesis InhibitorsIBA 09/2009
1	Vincristine (Oncovin)FDA LinkGeneric 08/2008
1	DNA (Deoxyribonucleic Acid)IBA 02/2008
1	Cyclin-Dependent Kinase Inhibitor p27IBA 08/2007
1	Notch1 ReceptorIBA 06/2007
1	F-Box ProteinsIBA 06/2007
1	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2005
1	Caspase 2IBA 08/2005

Therapy/Procedure

21	Therapeutics 05/2022 - 02/2008
5	Drug Therapy (Chemotherapy) 01/2022 - 02/2008
2	Hematopoietic Stem Cell Transplantation 01/2018 - 05/2013
2	Stem Cell Transplantation 04/2012 - 04/2011
1	Critical Care (Surgical Intensive Care) 12/2021
1	Catheters 01/2019
1	Artificial Respiration (Mechanical Ventilation) 01/2019
1	Transplantation 01/2019
1	Immunotherapy 01/2017
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2017
1	Treatment Delay 02/2016
1	Remission Induction 04/2012
1	Blood Transfusion (Blood Transfusions) 02/2008